The prognostic and predictive impact of inflammatory biomarkers in patients who have advanced-stage cancer treated with immunotherapy.
Mehmet Asim BilenDylan J MartiniYuan LiuColleen LewisHannah H CollinsJulie M ShabtoMehmet AkceHaydn T KissickBradley C CarthonWalid L ShaibOlatunji B AleseRathi N PillaiConor E SteuerChristina S WuDavid H LawsonRagini R KudchadkarBassel F El-RayesViraj A MasterSuresh R RamalingamTaofeek K OwonikokoR Donald HarveyPublished in: Cancer (2018)
Baseline and early changes in NLR, MLR, and PLR values were strongly associated with clinical outcomes in patients who received IO-based treatment regimens on phase 1 trials. Confirmation in a homogenous patient population treated on late-stage trials or outside of trial settings is warranted. These values may warrant consideration for inclusion when risk stratifying patients enrolled onto phase 1 clinical trials of IO agents.